Real World Data
Optimising the use of real world data to drive effective outcomes
Real world evidence (RWE) continues to drive healthcare and research discussions and decisions. ICON delivers Real World Intelligence®, bringing together innovative thinking and technology solutions to identify, generate, and communicate the clinical, safety and cost-effectiveness evidence that regulators, payers and providers demand.
Generate RWE using cross sectional studies and medical chart reviews
Download our white paper, Real World Evidence Generation: The Value of Cross-Sectional Studies and Medical Chart Reviews to learn how this hybrid approach to study design can be advantageous for generating real world evidence. Get insights on the issues you need to consider to ensure that your study is planned to produce robust scientific data that can be extrapolated beyond the study population.
Real World Data blogs and media contributions
-
Blog: Breaking into the Biosimilars Market: Opportunities & Challenges for Sponsors
Seven out of the 10 best selling drugs in 2015 were biologics.
-
Blog: NICE guidance on real-world evidence to usher innovative treatments
NICE published new guidance to give patients early access to innovative treatments by allowing greater flexibility considering a broader evidence base, making it easier for innovative and promising treatments to reach the patient incorporating the usage of real-world evidence.
-
Blog: 10 lessons learned about secondary “real world” data strategy
Insights and lessons learned about operationalising the use of real world data.
-
Blog: Encouraging patient participation in real world studies
Real world data offers an alternative approach to observational research, particularly to inform decisions on patient needs and preferences.
-
Blog: Improving access and reimbursement for specialty therapies
Clinical development can better satisfy the evidence needs of payers, and not incorporating the needs of payers early into trial designs risks the need to spend more money later on.
-
Blog: Five common literature reviews for RWE generation
In the evidence-based era of medicine and decision-making, literature reviews offer a faster and more cost-efficient method to gather intelligence.
-
-(1).jpg?crop=yes&w=545&h=286&itok=pw1KEA1X "iomt-(1)-(1)")
Blog: Digital intelligence for the clinical trial: How the IoMT is streamlining clinical operations
Rapid progress in connectivity and technology is inspiring innovative clinical trial design.
-
Blog: Real World Evidence: The Evolving Views of Regulators and Payers
RWE is being used to provide a more comprehensive data set for regulators’ and payers’ use in approval and reimbursement decisions.
-(1).jpg?itok=26fYfDiJ "iomt-(1)-(1)"){kind=icon}
Real World Data webinars
The landscape of real world data can be difficult to navigate
Database mapping provides a tool to systematically identify and evaluate RWD sources.
Effective ingestion and normalization of real world data sources
As more sources of anonymized Real World Data (RWD) become available, the ability to ingest, standardize and then link the collected disparate data sets is critical to creating insightful, analytical output.
Five common barriers to harmonised real world data (RWD)
Duplicate data environments, redundant data subscriptions, and siloed data access are not providing a good enough return on investment for Real World Evidence (RWE) generation
.jpg?crop=yes&w=555&h=292&a=0,24&itok=eYh_V-Mn "RWD-webinar-2-(2)"){kind=icon}
Optimise your RWE investments
Increasing drug development cost, the shift from volume to value-based pricing, and competition from generics and biosimilars, are forcing pharma and life science organizations are looking towards Real World Evidence (RWE) to prove the value – cost, safety, and effectiveness - of their products.
.jpg?crop=yes&w=555&h=292&a=0,24&itok=gwOJLyTc "RWD-webinar-4-(2)"){kind=icon}
How RWE continues to shape the late phase research landscape
Creating a comprehensive RWE strategy demands a focus on organizing and synthesizing the many real world data (RWD) asset options that are available to life sciences companies.
Real world evidence across the product lifecycle
Payment models and federal reforms are increasingly focused on the real world impact of treatments and devices. More regulatory guidance is being released in both the US and EU around the use of RWE to support and enhance submissions and product uptake.
Reduce the cost of post-market surveillance with real world data
Real-World Evidence (RWE) is derived from Real World Data (RWD), and early use of Real World Evidence can cut post-marketing study costs and Medical Device time-to-market.
Devices are especially good candidates for early RWE use since evidence collected in the context of actual patient care from previously approved versions or similar devices often can be used to supplement findings from clinical trials of the latest version in development.
RWD and Alzheimer's disease
Real world data such as sleep quality and quantity have clinical relevance in Alzheimer's disease, providing objective measures of sleep and activity patterns that are not subject to patient recall bias. Review the use of wearables in Alzheimer’s disease to provide objective measures of sleep and activity patterns that are not subject to patient recall bias.
Harnessing technology to maximise RWE value
Late phase research is undergoing rapid transformation due to the impact of healthcare digitalisation and the greater availability of and access to Real World Data (RWD).
Meeting evidentiary needs with EHRs
How can the abundance of Real World Data (RWD) from Electronic Health Records (EHRs) enhance your late phase research studies while decreasing study costs?
Receive more insights on Real World Data
Please visit ICON's Preference Centre and select 'Real World Evidence' under 'Topics of Interest' to receive new insights on oncology.